<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33829938</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7-8</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Comparison of the ability of the King's and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>478</StartPage><EndPage>485</EndPage><MedlinePgn>478-485</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.1903506</ELocationID><Abstract><AbstractText><i>Background:</i> Assessing clinical progression in amyotrophic lateral sclerosis (ALS) remains a challenge. We evaluated the validity and predictive capabilities of the King's and Milano-Torino Staging (MiToS) systems in a cohort of patients with ALS to demonstrate their benefit in clinical practice.<i>Methodology:</i> A cohort study was performed by including ALS incident cases in a referral center from 2007 to 2016. The staging systems were determined at time of diagnosis and follow-up. The standardized median times to reach each stage were computed. A multi-state model in the framework of the Cox model evaluated the predictive value of measurements. The survival C-statistic was reported as a measure of prediction ability.<i>Results:</i> Overall, 298 incident cases were included. The King's and MiToS systems described a progressive increase in the risk of dying with each elapsed stage. However, a lower resolution for late disease description for the King's system was observed, and late stages overlapped for the MiToS system. Slight variations in the staging systems appeared to improve performance based on validity and prediction abilities: (i) in the King's (<i>C</i>-statistic = 0.783), by adding a new stage involving the need for both gastrostomy and NIV: (ii) in the MiToS (<i>C</i>-statistic = 0.792), by merging stage 3 and stage 4 into a single stage 3.<i>Conclusion:</i> Both King's and MiToS are valid systems but have certain limitations. Variations in the staging systems may provide a more suitable framework for describing progression and survival. Further research is needed to evaluate the variations in the staging systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luna</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5990-7534</Identifier><AffiliationInfo><Affiliation>INSERM, University of Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST,Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, ALS expert centre, CHU Limoges,Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INSERM, University of Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST,Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, ALS expert centre, CHU Limoges,Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahmadi</LastName><ForeName>Sanae</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, ALS expert centre, CHU Limoges,Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lautrette</LastName><ForeName>G&#xe9;raldine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, ALS expert centre, CHU Limoges,Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontana</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6660-5315</Identifier><AffiliationInfo><Affiliation>Unit of Biostatistics, IRCCS ''Casa Sollievo della Sofferenza'', San Giovanni Rotondo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortelli</LastName><ForeName>Rosanna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Neurodegenerative Diseases, Department of Clinical Research in Neurology, University of Bari ''Aldo Moro'', at ''Pia Fondazione Cardinale G. Panico'', Lecce, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logroscino</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0423-3242</Identifier><AffiliationInfo><Affiliation>Unit of Neurodegenerative Diseases, Department of Clinical Research in Neurology, University of Bari ''Aldo Moro'', at ''Pia Fondazione Cardinale G. Panico'', Lecce, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari ''Aldo Moro'', Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preux</LastName><ForeName>Pierre-Marie</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0002-2171-2977</Identifier><AffiliationInfo><Affiliation>INSERM, University of Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST,Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre d'Epid&#xe9;miologie, de Biostatistique et de M&#xe9;thodologie de la Recherche, CHU Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Copetti</LastName><ForeName>Massimilano</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7960-5947</Identifier><AffiliationInfo><Affiliation>Unit of Biostatistics, IRCCS ''Casa Sollievo della Sofferenza'', San Giovanni Rotondo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benoit</LastName><ForeName>Marin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM, University of Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST,Limoges, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">King&#x2019;s</Keyword><Keyword MajorTopicYN="N">MiToS</Keyword><Keyword MajorTopicYN="N">clinical progression</Keyword><Keyword MajorTopicYN="N">prediction ability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>8</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33829938</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.1903506</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>